Rates of COVID-19-related Outcomes in Cancer compared to non-Cancer Patients.


Journal

medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986

Informations de publication

Date de publication:
15 Aug 2020
Historique:
entrez: 21 8 2020
pubmed: 21 8 2020
medline: 21 8 2020
Statut: epublish

Résumé

Cancer patients are a vulnerable population postulated to be at higher risk for severe COVID-19 infection. Increased COVID-19 morbidity and mortality in cancer patients may be attributable to age, comorbidities, smoking, healthcare exposure, and cancer treatments, and partially to the cancer itself. Most studies to date have focused on hospitalized patients with severe COVID-19, thereby limiting the generalizability and interpretability of the association between cancer and COVID-19 severity. We compared outcomes of SARS-CoV-2 infection in 323 patients enrolled prior to the pandemic in a large academic biobank (n=67 cancer patients and n=256 non-cancer patients). After adjusting for demographics, smoking status, and comorbidities, a diagnosis of cancer was independently associated with higher odds of hospitalization (OR 2.16, 95% CI 1.12-4.18) and 30-day mortality (OR 5.67, CI 1.49-21.59). These associations were primarily driven by patients with active cancer. These results emphasize the critical importance of preventing SARS-CoV-2 exposure and mitigating infection in cancer patients.

Identifiants

pubmed: 32817956
doi: 10.1101/2020.08.14.20174961
pmc: PMC7430598
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016520
Pays : United States

Commentaires et corrections

Type : UpdateIn

Références

Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
J Infect. 2020 Aug;81(2):318-356
pubmed: 32298677
JCO Glob Oncol. 2020 Jun;6:799-808
pubmed: 32511066
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Lancet Oncol. 2020 Jul;21(7):893-903
pubmed: 32479790
N Engl J Med. 2018 Jun 28;378(26):2456-2458
pubmed: 29949490
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JCO Glob Oncol. 2020 Apr;6:557-559
pubmed: 32250659
JAMA Netw Open. 2020 Jun 1;3(6):e2010651
pubmed: 32478845
Ann Oncol. 2020 Aug;31(8):1088-1089
pubmed: 32330541
Genet Med. 2020 Jan;22(1):102-111
pubmed: 31383942
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Science. 2020 Jun 19;368(6497):1290
pubmed: 32554570
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
Nat Commun. 2020 Nov 12;11(1):5749
pubmed: 33184277
J Hematol Oncol. 2020 Jun 10;13(1):75
pubmed: 32522278
Lancet Oncol. 2020 Jul;21(7):904-913
pubmed: 32479787

Auteurs

Lova Sun (L)

Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104.

Sanjna Surya (S)

Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104.

Anh N Le (AN)

Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104.

Heena Desai (H)

Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104.

Abigail Doucette (A)

Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, 19104.

Peter Gabriel (P)

Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, 19104.
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19104.

Marylyn Ritchie (M)

Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104.

Daniel Rader (D)

Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104.

Ivan Maillard (I)

Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104.
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19104.

Erin Bange (E)

Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104.

Alexander Huang (A)

Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104.

Robert H Vonderheide (RH)

Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104.
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19104.

Angela DeMichele (A)

Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104.
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19104.

Anurag Verma (A)

Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104.

Ronac Mamtani (R)

Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104.
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19104.

Kara N Maxwell (KN)

Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104.
Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104.
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19104.

Classifications MeSH